Search results

Found 25 pages
AUTHOR: Ian Mason

Results per page

10 20 50 100

Sort by

Relevance Date

17 Jan 2014:

Menarini launches male sexual health campaign

Menarini has launched ‘Firing Too Quickly’ – a UK campaign designed to raise public and healthcare provider awareness of premature ejaculation and its treatment. - News - PharmaTimes

by Ian Mason

www.pharmatimes.com/news/menarini_launches_male_sexual_health_campaign_1001378

10 Oct 2012:

Upbeat Novartis showcases MS portfolio at ECTRIMS

A raft of data on licensed and investigational multiple sclerosis treatments will be unveiled by Novartis at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, which opens today (October 10) in Lyon, France. -

by Ian Mason in Lyon

www.pharmatimes.com/news/upbeat_novartis_showcases_ms_portfolio_at_ectrims_976475

23 Feb 2012:

Novartis awaits Gilenya EMA review

The UK's Medicines and Healthcare products Regulatory Agency's latest ‘drug safety update’ (February) flags the increased cardiovascular monitoring required when patients are given their first dose of Novartis' oral multiple sclerosis drug

by Ian Mason

www.pharmatimes.com/news/novartis_awaits_gilenya_ema_review_975681

26 May 2011:

Eisai rolls out Halaven in UK

Eisai has officially launched Halaven in the UK, just a week after production of the novel breast cancer treatment started at the company’s £600 million manufacturing facility at Hatfield, Hertfordshire. - News - PharmaTimes

by Ian Mason

www.pharmatimes.com/news/eisai_rolls_out_halaven_in_uk_980982

27 Sep 2011:

HRT products ‘need stronger asthma warning’

Hormone replacement therapies should carry a stronger warning about the risk of causing potentially fatal asthma exacerbations in susceptible women, says the author of a major study presented at the European Respiratory Society congress in Amsterdam.

by Ian Mason

www.pharmatimes.com/news/hrt_products_need_stronger_asthma_warning_980334

27 May 2008:

Postmarketing data highlight efficacy of Raptiva

Two important milestones for Raptiva (efalizumab) – Merck Serono’s biological therapy for psoriasis – were reached this weekend. - News - PharmaTimes

by Ian Mason

www.pharmatimes.com/news/postmarketing_data_highlight_efficacy_of_raptiva_986983

10 May 2011:

Spotlight on superbugs at ECCMID meeting

There were brickbats a-plenty for big pharma at the European Congress of Clinical Microbiology and Infectious Diseases meeting in Milan, Italy, with drugmakers being criticised for their poor performance in the antibiotics R&D field. - News -

by By Ian Mason in Milan

www.pharmatimes.com/news/spotlight_on_superbugs_at_eccmid_meeting_981089

18 May 2010:

Treatment-switch trumps resistant-depression in teens

New research has flagged the value of early aggressive antidepressant treatment in adolescents who have failed to respond to SSRIs. - News - PharmaTimes

by Ian Mason

www.pharmatimes.com/news/treatment-switch_trumps_resistant-depression_in_teens_983221

28 Mar 2014:

AstraZeneca ramps up oncology pipeline

AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive  Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline. - News - PharmaTimes

by Ian Mason

www.pharmatimes.com/news/astrazeneca_ramps_up_oncology_pipeline_1001739

9 Sep 2014:

InterMune boosted by pirfenidone data

InterMune, which is in the process of being acquired by Roche for $8.3 billion, says that data over 72 weeks provides further evidence of a durable pirfenidone treatment benefit on multiple measures of idiopathic pulmonary fibrosis including

by Ian Mason

www.pharmatimes.com/news/intermune_boosted_by_pirfenidone_data_1002439